Pseudomonas aeruginosa LasA Protease in Treatment of Experimental Staphylococcal Keratitis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1681-1687

  Barequet, Irina S ^a   Simon, Guy J Ben ^a   Safrin, Mary ^a   Ohman, Dennis E ^b   Kessler, Efrat ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

LASA PROTEASE; LYSOSTAPHIN; PROTEINASE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; KERATITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PSEUDOMONAS AERUGINOSA; RABBIT; RISK BENEFIT ANALYSIS; STAPHYLOCOCCUS; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; CORNEA; HUMANS; KERATITIS; LYSOSTAPHIN; METALLOENDOPEPTIDASES; METHICILLIN; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PSEUDOMONAS AERUGINOSA; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 2142715955     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1681-1687.2004     Document Type: Article

References (38)

1. Alexandrakis, G., E. C. Alfonso, and D. Miller. 2000. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 107:1497-1502.
2. Alionte, L. G., B. M. Cannon, C. D. White, R. J. Caballero, R. J. O'Callaghan, and J. A. Hobden. 2001. Pseudomonas aeruginosa LasA protease and corneal infections. Curr. Eye Res. 22:266-271.
3. Asbell, P., and S. Stenson. 1982. Ulcerative keratitis. Survey of thirty years' laboratory experience. Arch. Ophthalmol. 100:77-80.
4. Baba, T., and O. Schneewind. 1996. Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. EMBO J. 15:4789-4797.
5. Brito, N., M. A. Falcon, A. Carnicero, A. M. Gutierrez-Navarro, and T. B. Mansito. 1989. Purification and peptidase activity of a bacteriolytic extracellular enzyme from Pseudomonas aeruginosa. Res. Microbiol. 140:125-137.
6. Callegan, M. C., J. M. Hill, M. S. Insler, J. A. Hobden, and R.J. O'Callaghan. 1992. Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr. Eye. Res. 11:1111-1119.
7. Callegan, M. C., R. J. O'Callaghan, and J. M. Hill. 1994. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin. Pharmacokinet. 27:129-149.
8. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
9. Dajcs, J. J., E. B. Hume, J. M. Moreau, A. R. Caballero, B. M. Cannon, and R. J. O'Callaghan. 2000. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Investig. Ophthalmol. Vis. Sci. 41:1432-1437.
10. Dajcs, J. J., B. A. Thibodeaux, E. B. Hume, X. Zheng, G. D. Sloop, and R. J. O'Callaghan. 2001. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr. Eye Res. 22:451-457.
11. Dajcs, J. J., B. A. Thibodeaux, D. O. Girgis, M. D. Shaffer, S. M. Delvisco, and R. J. O'Callaghan. 2002. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Investig. Ophthalmol. Vis. Sci. 43:3712-3716.
12. Daum, R. S., and J. B. Seal. 2001. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: our backs to the wall. Crit. Care Med. 29(Suppl.):N92-N96.
13. Dixon, R. E., J. S. Goodman, and M. G. Koenig. 1968. Lysostaphin; an enzymatic approach to staphylococcal disease. III. Combined lysostaphinmethicillin in therapy of established staphylococcal abscesses in mice. Yale J. Biol. Med. 41:62-68.
14. Goldstein, M. H., R. P. Kowalski, and Y. J. Gordon. 1999. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 106:1313-1318.
15. Gustin, J. K., E. Kessler, and D. E. Ohman. 1996. A substitution at His-120 in the LasA protease of Pseudomonas aeruginosa blocks enzymatic activity without affecting propeptide processing or extracellular secretion. J. Bacteriol. 178:6608-6617.
16. Harris, R. L., A. W. Nunnery, and H. D. Riley. 1967. Effects of lysostaphin on staphylococcal carriage in infants and children. Antimicrob. Agents Chemother. 7:110-112.
17. Harrison, E. F., and C. B. Cropp. 1967. Therapeutic activity of lysostaphin in experimental staphylococcal infections. Can. J. Microbiol. 13:93-97.
18. Hobden, J. A. 2002. Pseudomonas aeruginosa proteases and corneal virulence. DNA Cell Biol. 21:391-396.
19. Kessler, E. 1995. Β-Lytic endopeptidases. Methods Enzymol. 248:740-756.
20. Kessler, E., M. Safrin, J. C. Olson, and D. E. Ohman. 1993. Secreted LasA protease of Pseudomonas aeruginosa is a staphylolytic protease. J. Biol. Chem. 268:7503-7508.
21. Kessler, E., and D. E. Ohman. 1998. Staphylolysin, p. 1476-1478. In A. J. Barrett, N. D. Rawlings, and J. F. Woessner (ed.), Handbook of proteolytic enzymes, 1st ed. Academic Press, London, United Kingdom.
22. Kessler, E., M. Safrin, W. R. Abrams, J. Rosenbloom, and D. E. Ohman. 1997. Inhibitors and specificity of Pseudomonas aeruginosa LasA protease. J. Biol. Chem. 272:9884-9889.
23. Kessler, E., M. Safrin, J. K. Gustin, and D. E. Ohman. 1998. Elastase and the LasA protease of Pseudomonas aeruginosa are secreted with their propeptides. J. Biol. Chem. 273:30225-30231.
24. Liesegang, T. J. 1998. Bacterial and fungal keratitis, p. 159-219. In H. E. Kaufman, B. A. Baron, and M. B. McDonald (ed.), The cornea, 2nd ed. Butterworth-Heinemann, Boston, Mass.
25. Maffett, M., and D. M. O'Day. 1993. Ciprofloxacin-resistant bacterial keratitis. Am. J. Ophthalmol. 115:545-546.
26. Mansito, T. B., M. A. Falcon, J. Moreno, A. Carnicero, and A. M. Gutierrez-Navarro. 1987. Effects of staphylolytic enzymes from Pseudomonas aeruginosa on the growth and ultrastructure of Staphylococcus aureus. Microbios 49:55-64.
27. O'Brien T. P. 1997. Bacterial keratitis, p. 1139-1189. In J. H. Krachmer, M. J. Mannis, and E. J. Holland (ed.) Cornea and external disease: clinical diagnosis and management. Mosby-Year Book, St. Louis, Mo.
28. Patron, R. L., M. W. Climo, B. P. Goldstein, and G. L. Archer. 1999. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 43:1754-1755.
29. Perestelo, F. R., M. T. Blanco, A. M. Gutierre-Navarro, and M. A. Falcon. 1985. Growth inhibition of Staphylococcus aureus by a staphylolytic enzyme from Pseudomonas aeruginosa. Microbios Lett. 30:85-94.
30. Preston, M. J., P. C. Seed, D. S. Toder, B. H. Iglewski, D. E. Ohman, J. K. Gustin, J. B. Goldberg, and G. B. Pier. 1997. Contribution of proteases and LasR to the virulence of Pseudomonas aeruginosa during corneal infections. Infect. Immun. 65:3086-3090.
31. Quickel, K. E., R. Selden, J. R. Caldwell, N. F. Nora, and W. Schaffner. 1971. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl. Microbiol. 22:446-450.
32. Schaefer, F., O. Bruttin, L. Zografos, and Y. Guex-Crosier. 2001. Bacterial keratitis: a prospective clinical and microbiological study. Br. J. Ophthalmol. 85:842-847.
33. Schindler, C. A., and V. T. Schuhardt. 1964. Lysostaphin: A new bacteriolytic agent for Staphylococcus. Proc. Natl. Acad. Sci. USA 51:414-421.
34. Srinivasan, A., J. D. Dick, and T. M. Perl. 2002. Vancomycin resistance in staphylococci. Clin. Microbiol. Rev. 15:430-438.
35. Vessillier, S., F. Delorme, J. Bernillon, J. Saulnier, and J. Wallach. 2001. Hydrolysis of glycine-containing elastin pentapeptides by LasA protease, a metalloelastase from Pseudomonas aeruginosa. Eur. J. Biochem. 268:1049-1057.
36. Walsh, T. R., and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56: 657-675.
37. White, C. D., L. G. Alionte, B. M. Cannon, A. R. Caballero, R. J. O'Callaghan, and J. A. Hobden. 2001. Corneal virulence of LasA protease-deficient Pseudomonas aeruginosa PAO1. Cornea 20:643-646.
38. Zygmunt, W., and P. A. Tavormina. 1972. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug Res. 16:309-333.